Lorcaserin: an investigational serotonin 2C agonist for weight loss (Q37947448)

25 August 2017

Lorcaserin: an investigational serotonin 2C agonist for weight loss (English)

1 reference

25 August 2017

0 references

lorcaserin hydrochloride

1 reference

lorcaserin hydrochloride hemihydrate

ChEBI release 2020-05-28

ChEBI ID

65350

1 reference

ChEBI release 2020-05-28

Kathryn M Hurren

1

1 reference

PubMed ID

22011982

25 August 2017

Helen D Berlie

series ordinal

2

1 reference

25 August 2017

1 November 2011

1 reference

American Journal of Health-System Pharmacy

25 August 2017

1 reference

25 August 2017

68

1 reference

25 August 2017

21

1 reference

25 August 2017

2029-2037

1 reference

Prevalence and trends in obesity among US adults, 1999-2008

25 August 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Actual Causes of Death in the United States, 2000

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Annual medical spending attributable to obesity: payer-and service-specific estimates

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Outcome success in obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Appetite suppressants and valvular heart disease - a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

The potential use of selective 5-HT2C agonists in treating obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Reduced satiating effect of d -fenfluramine in serotonin 5-HT 2C receptor mutant mice

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Serotonergic drugs : effects on appetite expression and use for the treatment of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Pulmonary hypertension: therapeutic targets within the serotonin system.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Serotonin Reciprocally Regulates Melanocortin Neurons to Modulate Food Intake

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Activation of central melanocortin pathways by fenfluramine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Central serotonin and melanocortin pathways regulating energy homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Central nervous system control of food intake and body weight

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Multicenter, placebo-controlled trial of lorcaserin for weight management

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100638

31 March 2020

Identifiers

DOI

10.2146/AJHP100638

1 reference

25 August 2017

1 reference

PubMed ID

22011982